Bayer: Carcinoma, Non-Small-Cell Lung trials
The registry lists 28 Carcinoma, Non-Small-Cell Lung studies with Bayer as lead sponsor. 3 are open to participants now and 6 have results posted.
Phase 1 17Phase 2 8Phase 3 5(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid TumorsRecruitingNCT06914128Phase 1/2
- A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)RecruitingNCT06452277Phase 3
- First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)RecruitingNCT05099172Phase 1/2
- Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone MetastasesTerminatedNCT03996473Phase 1Results posted
- A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC).CompletedNCT00863746Phase 3Results posted
- A Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT00558636Phase 3Results posted
- A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00449033Phase 3Results posted
- A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT00300885Phase 3Results posted
- BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC)CompletedNCT00101413Phase 2Results posted
- A Study to Learn About How Food and Esomeprazole Affect the Level of BAY2927088 in the Blood When Taken Together in Healthy ParticipantsCompletedNCT06378658Phase 1
- A Study to Learn About How BAY2927088 Affects the Level of Midazolam in the Blood When Both Drugs Are Taken Together in Healthy ParticipantsCompletedNCT06360211Phase 1
- A Study to Learn About How Itraconazole and Carbamazepine Affect the Level of BAY2927088 in the Blood When These Drugs Are Taken Together by Healthy ParticipantsCompletedNCT06348888Phase 1
- A Study to Learn About How BAY2927088 Affects the Level of Dabigatran or Rosuvastatin in the Blood When These Drugs Are Taken Together in Healthy ParticipantsCompletedNCT06329895Phase 1
- A Study to Learn How BAY2927088 is Taken up and Handled by the Body in Healthy Male ParticipantsCompletedNCT06221475Phase 1
- A First-in-human Study to Learn How Safe the Study Treatment BAY2862789 is, to Find the Best Dose, How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, and How it Acts on Different Tumors in Participants With Advanced Solid TumorsCompletedNCT05858164Phase 1
- A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid TumorsActive, not recruitingNCT05614102Phase 1
- A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid TumorsActive, not recruitingNCT05537740Phase 1
- A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is, How This Combination Affects the Body, the Maximum Amount That Can be Given, How it Moves Into, Through and Out of the Body and Its Action Against Advanced Solid Cancers in AdultsTerminatedNCT04999202Phase 1
- Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its SafetyCompletedNCT04125693Phase 2
- A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced CancerCompletedNCT04069026Phase 1
- An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid TumorsCompletedNCT03735628Phase 1
- Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid TumorsCompletedNCT03102320Phase 1
- A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid TumorsCompletedNCT02576431Phase 2
- Phase I Dose Escalation and Expansion of Oral BAY 1143269 in Combination With Intravenous DocetaxelTerminatedNCT02439346Phase 1
- Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)CompletedNCT01069328Phase 1
- Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non-small-cell Lung CancerCompletedNCT00160069Phase 2
- Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non Small Cell Lung Cancer.CompletedNCT00160043Phase 2
- Evaluation of BAY 59-8862 in Taxane Resistant Non-Small Cell Lung Cancer PatientsCompletedNCT00044538Phase 2